Gender-affirming hormone therapy and cardiovascular prevention: adding another piece to an incomplete puzzle

Angela K Lucas-Herald^{1

2

3}, Paul Connelly⁴, Christian Delles³

Affiliations

¹ Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK.
² Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK.
³ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
⁴ Department of Endocrinology, Queen Elizabeth University Hospital, Glasgow, UK.

Editorial

Angela K Lucas-Herald et al. Eur J Prev Cardiol. 2026.

. 2026 Mar 5:zwag128.

doi: 10.1093/eurjpc/zwag128. Online ahead of print.

Angela K Lucas-Herald^{1

2

3}, Paul Connelly⁴, Christian Delles³

¹ Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK.
² Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK.
³ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
⁴ Department of Endocrinology, Queen Elizabeth University Hospital, Glasgow, UK.

No abstract available

Keywords: CVD; GAHT; risk; transgender.

Comment on

Gender-Affirming Hormone Therapy and Vascular Health: Walking the Line Between Caution and Confidence.
Grouthier V, Camoin M, Fawaz S, Mora P, Galioot A, Maury V, Lebourdon R, Montaudon M, Renault MA, Tabarin A, Couffinhal T. Grouthier V, et al. Eur J Prev Cardiol. 2026 Jan 5:zwaf789. doi: 10.1093/eurjpc/zwaf789. Online ahead of print. Eur J Prev Cardiol. 2026. PMID: 41490317